Dispatches from the FT Global Healthcare and biotech conference
Generics
“The major players still want to keep the full value chain for commodity products including APIs. For these customers the outsourcing opportunity is just interesting to note with respect to specialty technologies. On the other hand there are smaller players which are already partially virtual companies without their own manufacturing which need the full service we can provide them.”